


1 (previously presented). A compound having the formula I



in which:

Ring A is (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl;

R1, R2 independently of one another are H, F, Cl, Br, CF₃, OCF₃, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl, SCF₃, SF₅, OCF₂-CHF₂, (C₆-C₁₀)-aryl, (C₆-C₁₀)-aryloxy, OH, NO₂; or

R1 and R2 together with the phenyl ring form fused, partially or unsaturated bicyclic (C₆-C₁₀)-aryl;

R3 is H, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, (C₁-C₃)-alkyl-(C₃-C₈)-cycloalkyl, phenyl, (C₁-C₃)-alkyl-phenyl, or (C₁-C₃)-alkyl which is fully or partially substituted by F;

W is CH;

o is 1;

X is (C₁-C₆)-alkanediyl, where in the alkanediyl group one or more carbon atoms may be replaced by oxygen atoms;

n is 0-2;

R4 is H or (C₁-C₆)-alkyl;

R5 is H or (C₁-C₆)-alkyl;

R6 is H, (C₁-C₆)-alkyl or F;

R7 is H; F; (C₁-C₆)-alkoxy; (C₂-C₆)-alkenyl; (C₂-C₆)-alkynyl; (C₃-C₈)-cycloalkyl; phenyl which may be unsubstituted or substituted by one or more radicals from the group consisting of hydroxy, (C₁-C₆)-alkoxy, F and CF₃; (C₁-C₆)-alkyl which may be unsubstituted or substituted by one or more radicals selected from the group consisting of hydroxyl, phenyl, (C₁-C₆)-alkoxy and NR₁₁R₁₂;

with the proviso that R7 is not NR₁₁R₁₂ or (C₁-C₆)-alkoxy if R₆ = F;

R7 and R9 together with the atoms that carry them are pyrrolidine if n = 0;

R6 and R7 together with the carbon atom that carries them are (C₃-C₈)-cycloalkyl;

R8 is H, (C₁-C₆)-alkyl;

R9 is H, (C₁-C₆)-alkyl, (C₂-C₆)-alkenyl, (C₂-C₆)-alkynyl, (C₁-C₄)-alkyl-(C₆-C₁₀)-aryl, (C₁-C₄)-alkyl-O-(C₁-C₄)-alkyl, phenyl-(C₁-C₄)-alkyl;

R10 is H, (C₁-C₆)-alkyl-phenyl, (C₁-C₆)-alkyl;

R11 is H, (C₁-C₆)-alkyl-phenyl, (C₁-C₆)-alkyl;

R12 is H, (C₁-C₆)-alkyl-phenyl, (C₁-C₆)-alkyl;

a physiologically acceptable salt of the compound;

a solvate of the compound; or

a physiologically effective derivative of the compound.

2 (currently amended). The compound of Claim 1, in which

Ring A is (C₃-C₈)-cycloalkanediyl or (C₃-C₈)-cycloalkenediyl, ~~wherein one carbon atom of the (C₃-C₈)-cycloalkanediyl ring or the (C₃-C₈)-cycloalkenediyl ring may be replaced by an oxygen atom;~~

X is (C₁-C₆)-alkanediyl, wherein the C1 or C2 carbon atom (to Ring A) of the alkanediyl group may be replaced by an oxygen atom.

3 (previously presented). The compound of Claim 1, in which

Ring A is cis-cyclohexane-1,3-diyl

R1 is Br, CF₃, OCF₃, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl;

R2 is H, (C₁-C₆)-alkyl, O-(C₁-C₆)-alkyl or

R1 and R2 together with the phenyl ring form naphthyl;

R3 is CF₃, (C₁-C₆)-alkyl, (C₃-C₈)-cycloalkyl, phenyl;

W is CH;

o is 1;

X is CH₂O or CH₂-O-CH₂;

n is 0;

R6 is H or (C₁-C₆)-alkyl;

R7 is (C₁-C₆)-alkyl, where alkyl may be unsubstituted or substituted by phenyl;

R7 and R9 together with the atoms that carry them are pyrrolidine if n = 0;

R6 and R7 together with the carbon atom that carries them are (C₃-C₆)-cycloalkyl;

R8 is H; and

R9 is H, (C₁-C₆)-alkyl or benzyl.

4 (original). A pharmaceutical composition, comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.

5(original). The pharmaceutical composition of Claim 4, further comprising an active compound having a favorable effect on a metabolic disorder or disease.

6 (original). The pharmaceutical composition of Claim 4, further comprising an antidiabetic.

7 (original). The pharmaceutical composition of Claim 4, further comprising a lipid modulator.

8 (original). A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

9 (previously presented). A method for treating diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 1 to the patient.

10 (previously presented). The method of Claim 9, further comprising administering at least one further active compound for treating a disorder in which insulin is involved.

11 (original). A process for preparing a pharmaceutical comprising the compound of Claim 1, comprising the steps of:

(a) mixing the compound with a pharmaceutically acceptable carrier, and;

(b) bringing the mixture into a form suitable for administration.

12 (original). A pharmaceutical composition comprising the compound of Claim 2 and a pharmaceutically acceptable carrier.

13 (withdrawn). A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

14 (previously presented). A method for treating diabetes mellitus and its sequelae in a

patient, comprising administering a therapeutically effective amount of the compound of Claim 2 to the patient.

15 (original). A pharmaceutical composition comprising the compound of Claim 3 and a pharmaceutically acceptable carrier.

16 (original). A method for treating a disorder in which insulin resistance is involved in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.

17 (previously presented). A method for treating diabetes mellitus and its sequelae in a patient, comprising administering a therapeutically effective amount of the compound of Claim 3 to the patient.